Clinical trials: Peritoneal Cavity Cancer
- Condition Peritoneal Cavity Cancer
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
- Trial name
- NCT02272790
- Testing
- Adavosertib, Paclitaxel, Carboplatin
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MIRASOL (NCT04209855)
- Testing
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan
- Where
- 214 sites in United States, Australia and 19 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT05483933
- Testing
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 86 people
- Sponsor
- Shattuck Labs, Inc.
Ovarian Cancer
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with…
- Trial name
- NCT00976911
- Testing
- Bevacizumab, liposomal doxorubicin, paclitaxel
- Where
- 117 sites in Belgium, Bosnia and Herzegovina and 12 more
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Carcinoma, Fallopian Tube Cancer
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
- Trial name
- NCT01091428
- Testing
- Alisertib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 191 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759600
- Testing
- Niraparib
- Where
- 33 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Takeda
Neoplasms, Ovarian
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS…
- Trial name
- NCT05613088
- Testing
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 50 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer, Fallopian Tube Cancer
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03635489
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Ovarian Neoplasms, Peritoneal Neoplasms
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01846611
- Testing
- Trabectedin, DOXIL, Dexamethasone
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 581 people
- Sponsor
- Janssen Research & Development, LLC
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will…
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Trial name
- NCT01849874
- Testing
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 341 people
- Sponsor
- Pfizer
Fallopian Tube Cancer, Ovarian Cancer
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00617773
- Testing
- hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- Recepta Biopharma
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Ovarian Cancer, Fallopian Tube Cancer
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00428610
- Testing
- LY573636-sodium
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with…
- Trial name
- NCT03642132
- Testing
- Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Ovarian Cancer
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
The purpose of this study is to determine whether the investigational drug catumaxomab delivered in the planned treatment schedule is a safe and effective treatment for women with advanced ovarian cancer who experience a complete…
- Trial name
- NCT00377429
- Testing
- catumaxomab
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Neovii Biotech
Genital Neoplasms, Female, Fallopian Tube Neoplasms
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease…
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00191646
- Testing
- Gemcitabine, Paclitaxel, Carboplatin
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 919 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
- Trial name
- NCT00866697
- Testing
- Pazopanib
- Where
- 318 sites in United States, Australia and 15 more
- Volunteers
- 940 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Fallopian Tube Cancer
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC).
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT03657043
- Testing
- tisotumab vedotin
- Where
- 37 sites in United States, Belgium and 4 more
- Volunteers
- 98 people
- Sponsor
- Seagen Inc.
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
A Study of PF-06873600 in People With Cancer
The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer.
- Trial name
- NCT03519178
- Testing
- PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer